SG11202001931WA - Combination therapies of hepatitis b virus (hbv)-infected individuals using parapoxvirus ovis (ppvo) and at least one further antiviral drug - Google Patents
Combination therapies of hepatitis b virus (hbv)-infected individuals using parapoxvirus ovis (ppvo) and at least one further antiviral drugInfo
- Publication number
- SG11202001931WA SG11202001931WA SG11202001931WA SG11202001931WA SG11202001931WA SG 11202001931W A SG11202001931W A SG 11202001931WA SG 11202001931W A SG11202001931W A SG 11202001931WA SG 11202001931W A SG11202001931W A SG 11202001931WA SG 11202001931W A SG11202001931W A SG 11202001931WA
- Authority
- SG
- Singapore
- Prior art keywords
- ppvo
- hbv
- hepatitis
- virus
- combination therapies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24211—Parapoxvirus, e.g. Orf virus
- C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24211—Parapoxvirus, e.g. Orf virus
- C12N2710/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17189890 | 2017-09-07 | ||
| EP17196684 | 2017-10-16 | ||
| PCT/EP2018/074202 WO2019048640A1 (en) | 2017-09-07 | 2018-09-07 | Combination therapies of hepatitis b virus (hbv)-infected individuals using parapoxvirus ovis (ppvo) and at least one further antiviral drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202001931WA true SG11202001931WA (en) | 2020-04-29 |
Family
ID=63442656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202001931WA SG11202001931WA (en) | 2017-09-07 | 2018-09-07 | Combination therapies of hepatitis b virus (hbv)-infected individuals using parapoxvirus ovis (ppvo) and at least one further antiviral drug |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20200261520A1 (en) |
| EP (1) | EP3678697A1 (en) |
| JP (2) | JP2020533314A (en) |
| KR (1) | KR20200051685A (en) |
| CN (1) | CN111093697A (en) |
| AU (1) | AU2018327688B2 (en) |
| BR (1) | BR112020004539A2 (en) |
| CA (1) | CA3075206A1 (en) |
| CL (1) | CL2020000556A1 (en) |
| CU (1) | CU20200016A7 (en) |
| EC (1) | ECSP20016672A (en) |
| GE (1) | GEP20237518B (en) |
| IL (1) | IL273093A (en) |
| MA (1) | MA50071A (en) |
| MX (1) | MX2020002605A (en) |
| PH (1) | PH12020500445A1 (en) |
| SG (1) | SG11202001931WA (en) |
| TW (1) | TW201919675A (en) |
| UY (1) | UY37869A (en) |
| WO (1) | WO2019048640A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3906929A1 (en) | 2020-05-08 | 2021-11-10 | AiCuris GmbH & Co. KG | Letermovir for use in the prevention and the treatment of coronavirus infections |
| EP3906970B1 (en) | 2020-05-08 | 2022-07-06 | AiCuris GmbH & Co. KG | Parapoxvirus for conditioning and treatment of coronavirus infections |
| EP4157327A1 (en) * | 2020-05-28 | 2023-04-05 | The Regents Of The University Of Michigan | Compositions and methods for preventing and treating sars-cov-2 infection |
| WO2023083950A1 (en) | 2021-11-10 | 2023-05-19 | Aicuris Gmbh & Co. Kg | Parapoxvirus for preparing for and treatment of respiratory virus infections in combination with immunomodulators |
| WO2023083951A1 (en) | 2021-11-10 | 2023-05-19 | Aicuris Gmbh & Co. Kg | Parapoxvirus for preparing for and treatment of respiratory syncytial virus infections |
| WO2023083943A1 (en) | 2021-11-10 | 2023-05-19 | Aicuris Gmbh & Co. Kg | Parapoxvirus for preparing for and treatment of respiratory virus infections in combination with antivirals |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002004002A2 (en) * | 2000-07-11 | 2002-01-17 | Bayer Aktiengesellschaft | Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals and anticancer pharmaceuticals |
| US6632647B2 (en) * | 2000-07-11 | 2003-10-14 | Bayer Aktiengesellschaft | Use of strains of parapoxvirus ovis against organ fibrosis |
| CN1984666A (en) * | 2004-07-13 | 2007-06-20 | 爱库里斯股份有限两合公司 | Parapoxviruses in combination with other antiviral agents for the treatment of HIV/AIDS |
| CA2633400A1 (en) * | 2005-12-15 | 2007-06-21 | Bayer Healthcare Ag | Diaryl urea for treating virus infections |
| JP5699093B2 (en) * | 2012-01-05 | 2015-04-08 | アイキュリス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフトＡｉＣｕｒｉｓ ＧｍｂＨ ＆ Ｃｏ． ＫＧ | Recombinant protein of parapoxvirus Ovis and pharmaceutical composition derived therefrom |
| WO2017015451A1 (en) * | 2015-07-22 | 2017-01-26 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
-
2018
- 2018-09-06 TW TW107131294A patent/TW201919675A/en unknown
- 2018-09-07 KR KR1020207009442A patent/KR20200051685A/en not_active Application Discontinuation
- 2018-09-07 GE GEAP201815308A patent/GEP20237518B/en unknown
- 2018-09-07 CA CA3075206A patent/CA3075206A1/en active Pending
- 2018-09-07 SG SG11202001931WA patent/SG11202001931WA/en unknown
- 2018-09-07 UY UY0001037869A patent/UY37869A/en not_active Application Discontinuation
- 2018-09-07 AU AU2018327688A patent/AU2018327688B2/en active Active
- 2018-09-07 MA MA050071A patent/MA50071A/en unknown
- 2018-09-07 CU CU2020000016A patent/CU20200016A7/en unknown
- 2018-09-07 MX MX2020002605A patent/MX2020002605A/en unknown
- 2018-09-07 US US16/645,020 patent/US20200261520A1/en not_active Abandoned
- 2018-09-07 JP JP2020513816A patent/JP2020533314A/en active Pending
- 2018-09-07 BR BR112020004539-0A patent/BR112020004539A2/en not_active IP Right Cessation
- 2018-09-07 WO PCT/EP2018/074202 patent/WO2019048640A1/en unknown
- 2018-09-07 CN CN201880058406.1A patent/CN111093697A/en active Pending
- 2018-09-07 EP EP18762338.4A patent/EP3678697A1/en not_active Withdrawn
-
2020
- 2020-03-05 IL IL273093A patent/IL273093A/en unknown
- 2020-03-05 CL CL2020000556A patent/CL2020000556A1/en unknown
- 2020-03-05 PH PH12020500445A patent/PH12020500445A1/en unknown
- 2020-03-06 EC ECSENADI202016672A patent/ECSP20016672A/en unknown
-
2022
- 2022-08-02 JP JP2022123132A patent/JP2022167901A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CL2020000556A1 (en) | 2020-09-04 |
| UY37869A (en) | 2019-04-30 |
| JP2020533314A (en) | 2020-11-19 |
| AU2018327688B2 (en) | 2022-12-01 |
| TW201919675A (en) | 2019-06-01 |
| KR20200051685A (en) | 2020-05-13 |
| WO2019048640A1 (en) | 2019-03-14 |
| PH12020500445A1 (en) | 2020-11-09 |
| JP2022167901A (en) | 2022-11-04 |
| CA3075206A1 (en) | 2019-03-14 |
| GEP20237518B (en) | 2023-07-10 |
| CN111093697A (en) | 2020-05-01 |
| AU2018327688A1 (en) | 2020-03-19 |
| EP3678697A1 (en) | 2020-07-15 |
| CU20200016A7 (en) | 2020-11-30 |
| IL273093A (en) | 2020-04-30 |
| MA50071A (en) | 2020-07-15 |
| MX2020002605A (en) | 2020-07-20 |
| ECSP20016672A (en) | 2020-06-30 |
| BR112020004539A2 (en) | 2020-09-08 |
| US20200261520A1 (en) | 2020-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273093A (en) | Combination therapies of hepatitis b virus (hbv)-infected individuals using parapoxvirus ovis (ppvo) and at least one further antiviral drug | |
| ZA201806651B (en) | Elimination of hepatitis b virus with antiviral agents | |
| HK1251220A1 (en) | Novel tetracyclic 4-oxo-pyridine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection | |
| HK1255463A1 (en) | Combination therapy of an hbv capsid assembly inhibitor and an interferon | |
| HK1214509A1 (en) | Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same (hiv)(env) | |
| IL275427A (en) | Hepatitis b virus (hbv) vaccines and uses thereof | |
| HK1231402A1 (en) | Methods for the treatment of hepatitis b and hepatitis d virus infections b d | |
| HK1251010A1 (en) | Reagents for treatment of hepatitis b virus (hbv) infection and use thereof | |
| LT3416675T (en) | Treatment of hepatitis delta virus infection with interferon lambda | |
| IL275429A (en) | Methods and apparatus for the delivery of hepatitis b virus (hbv) vaccines | |
| EP3359577A4 (en) | Hepatitis c virus e1/e2 heterodimers and methods of producing same | |
| PL3463469T3 (en) | Combination of ledipasvir and sofosbuvir for use in the treatment of hepatitis b virus infections in humans | |
| EP3283503A4 (en) | Peptide and its derivatives capable of inhibiting replication of hepatitis c virus in human adipose-derived stem cells and hepatocytes | |
| HK1259329A1 (en) | Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis b virus | |
| EP3452595A4 (en) | Reagents for treatment of hepatitis b virus (hbv) infection and use thereof | |
| ZA202104076B (en) | Hepatitis b virus vaccine and uses thereof | |
| IL286484B (en) | Reagents for treatment of hepatitis b virus (hbv) infection and use thereof | |
| EA202090597A1 (en) | COMBINED THERAPY OF PATIENTS INFECTED WITH HEPATITIS B VIRUS (HBV) USING PARAPOXVIRUS OVIS (PPVO) AND AT LEAST ONE ADDITIONAL ANTIVIRAL AGENT | |
| AU2015901617A0 (en) | Reagents for treatment of hepatitis B virus (HBV) infection and use thereof |